Dermatitis News

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in a press release.

Severe disease, male sex, family history and prenatal factors were significantly associated with an increased risk for atopic march progression in infants with atopic dermatitis, according to a study.

The popular atopic dermatitis drug dupilumab has been found to be associated with an increased risk for cutaneous T-cell lymphoma in treated patients. It was the top dermatitis article in dermatology this year.

BOSTON — Chronic hand eczema can interfere with daily activities and have a significant negative impact on quality of life, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Patients who used dupilumab for atopic dermatitis had significantly lower risks for internal malignancies than patients using other therapies, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Arcutis Biotherapeutics has submitted a supplemental new drug application to the FDA for Zoryve cream 0.05% for the treatment of pediatric mild to moderate atopic dermatitis, according to a press release.

The FDA has approved Nemluvio, in conjunction with topical corticosteroids and/or calcineurin inhibitors, for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older, Galderma announced in a press release.

The FDA has approved Vtama cream 1% for atopic dermatitis in adults and children aged 2 years and older, Organon announced in a press release.

Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published in Advances in Therapy.